MRI for response assessment in metastatic bone disease

作者：Lecouvet F E^*; Larbi A; Pasoglou V; Omoumi P; Tombal B; Michoux N; Malghem J; Lhommel R; Vande Berg B C

来源：European Radiology, 2013, 23(7): 1986-1997.

DOI：10.1007/s00330-013-2792-3

• Bone
• Metastasis
• Treatment
• MRI
• Oncology

Beyond lesion detection and characterisation, and disease staging, the quantification of the tumour load and assessment of response to treatment are daily expectations in oncology. %26lt;br%26gt;Bone lesions have been considered %26quot;non-measurable%26quot; for years as opposed to lesions involving soft tissues and %26quot;solid%26quot; organs like the lungs or liver, for which response evaluation criteria are used in every day practice. This is due to the lack of sensitivity, specificity and measurement capabilities of imaging techniques available for bone assessment, i.e. skeletal scintigraphy (SS), radiographs and computed tomography (CT). %26lt;br%26gt;This paper reviews the possibilities and limitations of these techniques and highlights the possibilities of positron emission tomography (PET), but mainly concentrates on magnetic resonance imaging (MRI). %26lt;br%26gt;Practical morphological and quantitative approaches are proposed to evaluate the treatment response of bone marrow lesions using %26quot;anatomical%26quot; MRI. Recent developments of MRI, i.e. dynamic contrast-enhanced (DCE) imaging and diffusion-weighted imaging (DWI), are also covered. %26lt;br%26gt;aEuro cent MRI offers improved evaluation of skeletal metastases and their response to treatment. %26lt;br%26gt;aEuro cent This new indication for MRI has wide potential impact on radiological practice. %26lt;br%26gt;aEuro cent MRI helps meet the expectations of the oncological community. %26lt;br%26gt;aEuro cent We emphasise the practical aspects, with didactic cases and illustrations.

• 出版日期2013-7